177 related articles for article (PubMed ID: 18331603)
1. Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.
Moreau AS; Sebti Y; Duhamel A; Roccaro AM; Coiteux V; Gastinne T; Le Friec G; Burwick N; Amiot L; Ho AW; Poulain S; Hennache B; Hunter ZR; Dessaint JP; Ghobrial IM; Treon SP; Facon T; Zorn E; Leleu X
Eur J Haematol; 2008 Jun; 80(6):503-9. PubMed ID: 18331603
[TBL] [Abstract][Full Text] [Related]
2. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity.
Anagnostopoulos A; Eleftherakis-Papaiakovou V; Kastritis E; Tsionos K; Bamias A; Meletis J; Dimopoulos MA; Terpos E
Br J Haematol; 2007 Jun; 137(6):560-8. PubMed ID: 17451406
[TBL] [Abstract][Full Text] [Related]
3. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
4. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
5. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
6. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
7. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
Konoplev S; Medeiros LJ; Bueso-Ramos CE; Jorgensen JL; Lin P
Am J Clin Pathol; 2005 Sep; 124(3):414-20. PubMed ID: 16191510
[TBL] [Abstract][Full Text] [Related]
9. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
11. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
[TBL] [Abstract][Full Text] [Related]
12. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
[TBL] [Abstract][Full Text] [Related]
13. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Kyrtsonis MC; Vassilakopoulos TP; Angelopoulou MK; Siakantaris P; Kontopidou FN; Dimopoulou MN; Boussiotis V; Gribabis A; Konstantopoulos K; Vaiopoulos GA; Fessas P; Kittas C; Pangalis GA
Ann Hematol; 2001 Dec; 80(12):722-7. PubMed ID: 11797112
[TBL] [Abstract][Full Text] [Related]
14. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
Leleu X; Moreau AS; Weller E; Roccaro AM; Coiteux V; Manning R; Nelson M; Leduc R; Robu D; Dupire S; Hatjiharissi E; Burwick N; Darre S; Hennache B; Treon SP; Facon T; Gertz MA; Ghobrial IM
Leuk Lymphoma; 2008 Jun; 49(6):1104-7. PubMed ID: 18452095
[TBL] [Abstract][Full Text] [Related]
15. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
Schop RF; Van Wier SA; Xu R; Ghobrial I; Ahmann GJ; Greipp PR; Kyle RA; Dispenzieri A; Lacy MQ; Rajkumar SV; Gertz MA; Fonseca R
Cancer Genet Cytogenet; 2006 Sep; 169(2):150-3. PubMed ID: 16938573
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.
Morra E; Cesana C; Klersy C; Barbarano L; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Miqueleiz S; Bernuzzi P; Nosari AM; Lazzarino M
Leukemia; 2004 Sep; 18(9):1512-7. PubMed ID: 15322559
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis in Waldenström's macroglobulinemia.
Terpos E; Tasidou A; Kastritis E; Eleftherakis-Papaiakovou E; Gavriatopoulou M; Migkou M; Dimopoulos MA
Clin Lymphoma Myeloma; 2009 Mar; 9(1):46-9. PubMed ID: 19362971
[TBL] [Abstract][Full Text] [Related]
18. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
Pasricha SR; Juneja SK; Westerman DA; Came NA
J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L; Goldaniga M; Guffanti A; Broglia C; Cortelazzo S; Rossi A; Morra E; Colombi M; Callea V; Pogliani E; Ilariucci F; Luminari S; Morel P; Merlini G; Gobbi P
J Clin Oncol; 2005 Jul; 23(21):4662-8. PubMed ID: 16034042
[TBL] [Abstract][Full Text] [Related]
20. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.
Owen RG; Barrans SL; Richards SJ; O'Connor SJ; Child JA; Parapia LA; Morgan GJ; Jack AS
Am J Clin Pathol; 2001 Sep; 116(3):420-8. PubMed ID: 11554171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
